These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6376827)

  • 1. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.
    Kurth KH; Schröder FH; Tunn U; Ay R; Pavone-Macaluso M; Debruyne F; de Pauw M; Dalesio O; ten Kate F
    J Urol; 1984 Aug; 132(2):258-62. PubMed ID: 6376827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trail comparing doxorubicin hydrochloride, ethoglucid and TUR-alone.
    Kurth KH; Debruyne FJ; Senge T; Carpentier PJ; Riedl H; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1985; 185B():135-42. PubMed ID: 3898138
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
    Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
    J Urol; 1997 Aug; 158(2):378-84. PubMed ID: 9224307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
    Kurth K; Schroeder FH; Debruyne F; Senge T; Pavone-Macaluso M; de Pauw M; ten Kate F; Sylvester R
    Prog Clin Biol Res; 1989; 303():481-90. PubMed ID: 2675005
    [No Abstract]   [Full Text] [Related]  

  • 5. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
    Flamm J; Bucher A; Höltl W; Albrecht W
    J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative doxorubicin instillation in recurrent superficial bladder cancer.
    Kubota Y; Noguchi S; Shuin T; Moriyama M; Hosaka M; Satomi Y; Furuhata A; Kondo I; Sakuramoto T; Yao M
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S56-9. PubMed ID: 3664944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer.
    Flamm J
    Eur Urol; 1990; 17(2):119-24. PubMed ID: 2178939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
    Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
    Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
    Bouffioux C; Denis L; Oosterlinck W; Viggiano G; Vergison B; Keuppens F; De Pauw M; Sylvester R; Cheuvart B
    J Urol; 1992 Aug; 148(2 Pt 1):297-301. PubMed ID: 1635122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 12. The ultrastructure of transitional cell carcinomas of the human urinary bladder treated with ethoglucid or mitomycin.
    Stewart RJ; Lawson AH; Weaver JP
    J Urol; 1988 Jun; 139(6):1355-8. PubMed ID: 3373614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavitary Epodyl for multiple non-invasive, highly differentiated bladder tumours.
    Colleen S; Ek A; Hellsten S; Lindholm CE
    Scand J Urol Nephrol; 1980; 14(1):43-5. PubMed ID: 7375840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.
    Flamm J; Bucher A
    Br J Urol; 1991 Jan; 67(1):70-3. PubMed ID: 1993279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
    Bouffioux C; Kurth KH; Bono A; Oosterlinck W; Kruger CB; De Pauw M; Sylvester R
    J Urol; 1995 Mar; 153(3 Pt 2):934-41. PubMed ID: 7853578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of pathologic changes in the urinary epithelium on the absorption of ethoglucide (Epodyl) from the bladder].
    Lunglmayr G; Kratzik C; Mattausch M
    Wien Klin Wochenschr; 1984 Mar; 96(5):182-5. PubMed ID: 6730516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.
    van der Meijden AP; Kurth KH; Oosterlinck W; Debruyne FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S95-8. PubMed ID: 1394828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ureteropyeloscopic tumour treatment.
    Mathiasen H; Frimodt-Möller PC; Nielsen HV
    Scand J Urol Nephrol Suppl; 1988; 110():201-3. PubMed ID: 3187408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.
    Mufti GR; Virdi JS; Hall MH
    Br J Urol; 1990 Jan; 65(1):32-5. PubMed ID: 2310930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early adjuvant adriamycin in superficial bladder carcinoma.
    Schulman CC; Denis LJ; Costerlinck W; De Sy W; Chantrie M; Bouffioux C; Van Cangh PJ; Van Erps P; De Sloover C
    Prog Clin Biol Res; 1984; 162B():151-62. PubMed ID: 6390444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.